- Let's make a deal May 6
There's been a high-stakes reshuffling of the deck in the global pharmaceutical industry, and the latest company to show its hand is Germany's Bayer, which said Tuesday morning that it's purchasing Merck's consumer care unit for $14.2 billion. That means the company that pioneered aspirin — and now also makes Alka-Seltzer, Aleve, and Flintstones vitamins, among other brands — will own Claratin, Afrin, Coppertone, and Dr. Scholl's foot products. But the bigger prize for Bayer, assuming the deal goes through, is that it will be the No. 2 consumer drugmaker in the world, after Johnson & Johnson.- -
THE WEEK'S AUDIOPHILE PODCASTS: LISTEN SMARTER
- The U.S. Marines are developing laser weapons. Here's why.
- 3 horrific inaccuracies in Homeland's depiction of Islamabad
- 10 things you need to know today: October 21, 2014
- Gamergate has backfired spectacularly on its nincompoop perpetrators
- 43 TV shows to watch in 2014
- Why the Supreme Court is allowing Texas to hold an unconstitutional election
- How to be the most productive person in your office — and still get home by 5:30 p.m.
- Paul Krugman, Amazon, and the left's backwards view of book-industry titans
- The one thing the New Atheists get right about religion
- How 1,000-year lifespans could remake the economy
Subscribe to the Week